Loading...

Sandoz Group AG

0SAN.LLSE
Healthcare
Medical - Pharmaceuticals
£49.96
£1.11(2.28%)

Sandoz Group AG (0SAN.L) Financial Performance & Income Statement Overview

Review Sandoz Group AG (0SAN.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
-8.60%
8.60%
Operating Income Growth
262.60%
262.60%
Net Income Growth
-100.00%
100.00%
Operating Cash Flow Growth
101.65%
101.65%
Operating Margin
14.91%
14.91%
Gross Margin
47.30%
47.30%
Net Profit Margin
0.00%
ROE
0.00%
ROIC
10.00%
10.00%

Sandoz Group AG (0SAN.L) Income Statement & Financial Overview

Analyze Sandoz Group AG’s 0SAN.L earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q2 2024Q4 2023Q3 2023
Revenue$4.06B$5.06B$2.12B$2.52B
Cost of Revenue$2.12B$2.68B$1.20B$1.43B
Gross Profit$1.93B$2.38B$920.98M$1.09B
Gross Profit Ratio$0.48$0.47$0.43$0.43
R&D Expenses$331.78M$489.00M$170.74M$203.00M
SG&A Expenses$896.66M$1.25B$517.26M$615.00M
Operating Expenses$906.64M$2.05B$971.45M$1.16B
Total Costs & Expenses$3.03B$4.73B$2.17B$2.58B
Interest Income$37.87M$0.00$47.10M$51.26M
Interest Expense$235.14M$0.00$0.00$0.00
Depreciation & Amortization$233.10M$209.00M$79.06M$94.00M
EBITDA$126.55M$541.00M$42.47M$50.50M
EBITDA Ratio$0.03$0.11$0.02$0.02
Operating Income$1.03B$332.00M-$36.59M-$43.50M
Operating Income Ratio$0.25$0.07-$0.02-$0.02
Other Income/Expenses (Net)-$1.24B-$128.00M-$60.98M-$72.50M
Income Before Tax-$213.69M$204.00M-$97.57M-$116.00M
Income Before Tax Ratio-$0.05$0.04-$0.05-$0.05
Income Tax Expense-$63.57M$53.00M$31.96M$38.00M
Net Income-$150.00M$150.00M-$66.45M-$79.00M
Net Income Ratio-$0.04$0.03-$0.03-$0.03
EPS-$0.35$0.35-$0.15-$0.18
Diluted EPS-$0.35$0.35-$0.15-$0.18
Weighted Avg Shares Outstanding$430.20M$430.20M$429.72M$429.72M
Weighted Avg Shares Outstanding (Diluted)$434.00M$432.20M$429.72M$429.72M

Over the last four quarters, Sandoz Group AG achieved steady financial progress, growing revenue from $2.52B in Q3 2023 to $4.06B in Q4 2024. Gross profit stayed firm with margins at 48% in Q4 2024 versus 43% in Q3 2023. Operating income totaled $1.03B in Q4 2024, maintaining a 25% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $126.55M. Net income dropped to -$150.00M, with EPS at -$0.35. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;